US stock futures dip as Trump’s firing of Cook sparks Fed independence fears
On Thursday, BofA Securities adjusted its stance on RxSight Inc. (NASDAQ:RXST), moving from a Buy to an Underperform rating. This downgrade was accompanied by a significant reduction in the price target, now set at $22, down from the previous target of $36. According to InvestingPro data, the stock has already declined by over 45% in the past six months, though the company maintains a "GREAT" financial health score of 3.09 out of 5. The revision follows RxSight’s preannouncement of a first-quarter revenue shortfall of 5% and a downward revision of its 2025 revenue guidance by 12% at the midpoint. Despite these challenges, InvestingPro data shows the company achieved impressive revenue growth of 57% in the last twelve months, with a strong balance sheet featuring a current ratio of 11.36.
The downgrade comes in response to a quarterly performance that fell short of expectations, with RxSight experiencing a 6% sequential decline in revenue, contrasting sharply with the -1% decline anticipated by analysts. BofA Securities pointed out that the market had not foreseen the extent of the miss or the reduced guidance, which is likely to put the stock under pressure.
According to BofA Securities, the revised guidance indicates a deceleration in growth for the remainder of the year. This has led to concerns regarding potential market saturation for RxSight’s light adjustable lens (LAL) products, a decrease in procedure volumes from new light delivery device (LDD) installations, and the overall visibility of the company’s management. For deeper insights into RxSight’s market position and growth potential, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro, which covers these and other crucial metrics for over 1,400 US stocks.
BofA Securities expressed a lack of confidence in RxSight’s ability to surpass financial forecasts, suggesting that the company may need multiple quarters of renewed top-line growth to regain investor trust and achieve a higher stock valuation. The firm justified the lower price objective by applying a 3x enterprise value to estimated 2026 sales, a decrease from the previous 5x multiple.
The report closed with a summary of the updated model, reflecting the new expectations for RxSight’s financial performance in light of the recent announcements and market outlook.
In other recent news, RxSight Inc. reported a first-quarter revenue of $37.9 million for 2025, marking a 28% increase year-over-year but falling short of the consensus estimate of $39.8 million. The company also revised its 2025 revenue guidance downward by 12% to a range of $160-175 million. Despite these challenges, RxSight saw strong sales in its Light Delivery Devices, exceeding expectations with 73 units sold. Analyst firms have adjusted their outlooks, with Needham maintaining a Buy rating and a $43 price target, while BofA Securities lowered its price target to $36 but also retained a Buy rating. Stifel reduced its price target to $28, maintaining a Hold rating, while Jefferies cut its target to $50 but kept a Buy rating. BTIG also lowered its price target to $44, maintaining a Buy rating, noting that RxSight’s fourth-quarter revenue aligned with expectations at $40.2 million, a 41% increase. Analysts have expressed optimism about the company’s long-term prospects, particularly with potential international market approvals. Despite the challenges, RxSight’s valuation remains attractive to some analysts due to its growth potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.